What to ask about a product before you agree

What to ask about the sore area first

Talk first about the aching spot rather than the treatment name in a brochure. Point to it, give its start date, and show the movement that causes soreness.

The exam can show swelling, weakness, tender areas, or less motion. A scan may suggest wear, but neither one can promise that a procedure will help.

Ask whether gentle exercise, heat, cold, a brace, or medicine still deserves a try. Simpler care may be enough, and it may carry less cost or risk.

Mention locking, repeated swelling, lost support, or soreness that wakes you. Each detail helps the clinician check for another cause.

What to bring and what to ask

Bring your medicine list, old scan reports, and a note about earlier care. Add one activity that the sore joint now limits.

Ask for the exact procedure and the material that will be used. A broad name doesn't tell you where the material came from or how it was prepared.

Product status means the rules tied to that material and its planned use. It tells you about review, not whether your soreness will ease.

Ask for three plain statements: what the exam shows, what care might help, and what is unknown. For example, swelling is shown, arthritis may be the cause, and relief remains uncertain.

What to do if the ache keeps returning

If soreness returns despite simple care, QC Kinetix may explain regenerative treatments made with blood or another body tissue. The joint is examined before any clinic procedure.

Ask whether the clinic would draw your blood, spin it, and use the prepared part in a joint shot. A direct description is more useful than any broad product name.

Also ask about cost, recovery, later care, and which symptoms require a call. No product name can predict how your joint will respond.

The proposed treatment should match the problem found on your exam and the activity you want back. If that match isn't clear, ask the clinician to explain it again.

Sources

1. FDA's guidance on the 21 CFR 1271.10(a) criteria of MINIMAL MANIPULATION and HOMOLOGOUS USE is the rule that decides whether a cell or tissue product may be offered as a lightly-regulated 'section 361' HCT/P or requires full drug approval as a 'section 351' biologic. Docket FDA-2017-D-6146; the revised July 2020 version extended the agency's period of enforcement discretion through 31 May 2021 - which has now expired, so products outside 361 need an approved application or an active IND.

   US Food and Drug Administration, CBER and CDRH — Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use. FDA, 2020.

2. FDA's 6 December 2019 public safety notification followed multiple serious adverse events in Nebraska patients treated with unapproved products marketed as containing exosomes. FDA states there are currently no FDA-approved exosome products, that exosomes used to treat human disease are regulated as drugs and biologics subject to premarket review, and that clinics claiming otherwise are 'simply untrue' - naming clinics that also market violative stem cell products.

   US Food and Drug Administration — Public Safety Notification on Exosome Products. FDA, 2019.

3. On 25 June 2019 US District Judge Ursula Ungaro of the Southern District of Florida permanently enjoined US Stem Cell Clinic LLC, US Stem Cell Inc. and their chief scientific officer from manufacturing or distributing stromal vascular fraction products until they comply with the law. The Department of Justice had filed in May 2018; on 3 June 2019 the court granted summary judgment, concluding the defendants had ADULTERATED AND MISBRANDED cellular products made from patients' own adipose tissue. Autologous origin is not a regulatory exemption.

   Sharpless NE (Acting Commissioner of Food and Drugs) — Statement on stem cell clinic permanent injunction and FDA's ongoing efforts to protect patients from risks of unapproved products. FDA Press Announcements, 2019.

4. In January 2025 the Federal Trade Commission banned the co-founders of a stem cell institute and their companies from marketing stem cell treatments and ordered them to pay more than $5.1 million in refunds and civil penalties. Deceptive EFFICACY ADVERTISING, not merely unapproved manufacturing, is independently actionable - the FTC polices what a clinic promises as well as what it injects.

   US Federal Trade Commission — Stem Cell Institute Co-Founders and Companies Banned from Marketing Stem Cell Treatments and Ordered to Pay More Than $5.1 Million for Refunds and Civil Penalties. FTC Press Release, 2025.

5. FDA's public list of licensed cellular and gene therapy products is the checkable answer to 'is this FDA-approved?'. A product not on that list, and not being administered under an active IND, is not an approved therapy however it is described in a brochure. For orthopedics the list is short and its cartilage entry is MACI, indicated for focal full-thickness knee defects.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Approved Cellular and Gene Therapy Products. FDA, 2026.

6. MACI (autologous cultured chondrocytes on a porcine collagen membrane, Vericel; STN BL 125603) IS an FDA-LICENSED cell therapy - and its approved indication is narrow and specific: repair of symptomatic, single or multiple FULL-THICKNESS cartilage defects OF THE KNEE, with or without bone involvement, in adults. It is not approved for osteoarthritis. The existence of one licensed cartilage cell therapy for focal defects is the sharpest available way to show what a licensed 'regeneration' product actually looks like, and how far it is from an injection for a worn joint.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — MACI (autologous cultured chondrocytes on porcine collagen membrane). FDA, 2024.